{"id":4984,"date":"2022-03-01T17:18:52","date_gmt":"2022-03-01T08:18:52","guid":{"rendered":"https:\/\/www.sanyo-chemical.co.jp\/eng\/?p=4984"},"modified":"2022-03-01T17:18:52","modified_gmt":"2022-03-01T08:18:52","slug":"non-biological-surgical-sealant-independent-of-blood-coagulation-of-patients-aquabrid-commences-clinical-use-in-taiwan","status":"publish","type":"post","link":"https:\/\/www.sanyo-chemical.co.jp\/eng\/archives\/4984","title":{"rendered":"Non-biological surgical sealant independent of blood coagulation of patients AQUABRID\u00ae commences clinical use in Taiwan."},"content":{"rendered":"
Sanyo Chemical Industries, Ltd. (Head Office: Higashiyama ku, Kyoto; President and CEO: Akinori Higuchi; hereinafter “Sanyo Chemical”) announces that AQUABRID local brand name: Hydrofit \u00ae has obtained regulatory approval* as a medical device in Taiwan and clinical use commenced in December 2021. AQUABRID is a non absorbent topical hemostatic sealant for the central circulatory system manufactured by Sanyo Chemical and marketed by Terumo Corporation, a medical device manufacturer , (Head Office: Shibuya ku, Tokyo; CEO:Shinjiro Sato).<\/p>\n
<\/p>\n